Speakers

Elsa Abranches holds a degree in Chemical Engineering and a Ph.D. in Stem Cell Biotechnology, from the Technical University of Lisbon, Portugal. Elsa has over 20 years of experience in stem cell biotechnology, standardization and Advanced Therapies regulation areas, ranging from applied research...

Khalid Al-Kinani is a distinguished Professor and Department Chair at the University of Baghdad, renowned for his expertise in the field of biologics. He also serves as a mamber of the 2nd Medicines Reguistration Committee at the Iraqi Ministry of Health (MOH) and a former Head of Biologics and...

Dr. Can Araman is a Senior Manager heading the Protein Formulation Laboratory at Merck Life Science KGaA, Process Solutions department in Darmstadt, Germany. His team is working on delivering solutions to challenges in protein formulations stemming mainly from viscosity and aggregation of...

Baptiste Balbuena is a Biomanufacturing Engineer MSAT EMEA passioned by bioprocessing. Holder of a master’s degree in project management and biotechnologies innovation from Montpellier University, he dedicated last years to technically support customers with various problematics concerning...

I started my career in the pharmaceutical industry in 2000 as a Clinical Research Associate (CRA) at Pfizer, where I gained hands-on experience in clinical research from the very beginning. This role provided me with a fundamental understanding of clinical trial operations, monitoring and...

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology...

Julia has been researching on immune proteins already during her PhD at a leading hospital in the US. Afterwards Julia was involved in development of various therapeutics from preclinics up to clinical and market access strategy development in the industry. After combining this expertise with...

Dr. Nicola Beltraminelli joined Innate Pharma as Vice President and Chief Development Officer in January 2022 and was recently appointed as Head of Reasearch Early Development of the organization. Dr. Beltraminelli brings 25 years of biotech experience to the role, and specifically in the...

I am a Technical Project Leader at Roche, specializing in biologics, antibody engineering, and tumor-activated cytokine fusions. With eight years of experience in antibody and VHH phage display, bispecific antibody design, and protein engineering, I lead the development of IND-ready molecules and...

Sara Bonetti is Senior Scientist at Salipro Biotech, a company located in Stockholm, Sweden, working on stabilizing challenging drug targets for drug discovery. Prior to joining Salipro Biotech, Sara obtained her PhD in Biochemistry and Molecular Biology from the University of...

Prof. Frederic Bouder has developed policy-oriented research on risk communication and risk regulation, with a strong transatlantic and comparative dimension. His interest for medicines has taken central stage in his career including in the area of vaccines and biotechnology. His research interests ...

Diego has more than two decades of venture capital experience and has developed a solid experience in creating, growing and exiting ventures in therapeutics and medical devices. He served as chairman and non-executive director in Endoart (acquired by Allergan), Endosense (acquired by St...

Dr. Luigi Buonaguro is the Director of the Innovative Immunological Models at the National Cancer Institute - IRCCS “Pascale ”, Naples – Italy. He is an expert in identification and characterization of tumor antigens for preventive/therapeutic cancer vaccine development. His focus is mostly on...

A/Prof Andre Choo obtained his PhD from the University of Technology Sydney focusing on the molecular engineering of antibody fragments and immunotoxins. He was also involved in the characterization of a mAb that induced apoptosis of kappa-myelomas.  This is currently pursued by HaemaLogiX in Phase ...

Dr. Silvia Crescioli is a Business Intelligence Creator at The Antibody Society working on business intelligence and educational research projects. Since 2021, she collaborates to the "Antibodies to watch" editorials in mAbs, reviewing antibody therapeutics recently approved or in...

Dr. Camille Dagallier is a Laboratory & Process Development Senior Scientist at Sanofi, where she has been advancing drug product development since 2015. A graduate of ESPCI Paris with a master's in polymer science, she earned her PhD in colloid physics from the University of...

Roberto De Luca graduated in Biology at ETH Zürich. He performed his PhD studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of tumors. Dr. De Luca is author of several peer-reviewed publications in international scientific journals.

Gundo Diedrich is Executive Director of Antibody Engineering at MacroGenics. His work focuses on the discovery, engineering, and expression of antibodies as well as the development of the company’s multispecific antibody platform. Gundo received a Ph.D. in Chemistry from the Max-Planck Institute...

Current experience: Dr. Joan D'souza is a Pharmacovigilance Physician and a Consultant. She has expertise in pre and post-marketing safety surveillance of drugs and medical devices. Previous experience: A firm believer in sharing her knowledge: The DIA, World Drug Safety Congress; ...

Stefan Dübel is Full Professor of Biotechnology and Director of the corresponding department at the Technical University of Braunschweig, Germany. After completing his PhD at the University of Heidelberg, he joined the German Cancer Research Center (DKFZ) in 1989, where he pioneered in vitro...

Dr Anselm Ebert, PhD holds the position of Business Development Director at H&T Presspart. Dr Ebert oversees the strategic management of the new product development process and manages new product introductions for H&T Presspart. Before joining H&T Presspart he was Director of Product...

Marisa has >10 years of experience in life sciences and therapeutics, specializing in gene therapy, neurotechnology, and business development. She joined Oligo Factory in May 2024 as the Director of Business Development covering the Western US & Asia-Pacific regions where she leads strategic ...

I have more than 20 years of experience in the pharmaceutical industry and have held various positions in clinical trial management, procurement and medical affairs. As an Industry Clinical Collaboration Leader, I focus on bringing new and innovative treatment combinations to patients through...

Kevin began his career at Cambridge Antibody Technology (now part of AstraZeneca) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the...

I am a researcher in Translational Modelling & Simulation at Roche. I support large molecule projects through model-based predictions that e.g. support the optimization of compound dosing schedules, predict First-In-Human dosing or select a lead drug candidate. I also develop in silico models...

Ettore Gilardoni is Head of Mass Spectrometry at Philochem AG. The team main activities vary from biodistribution of small organic molecules in biospecimens; biopharmaceuticals characterization, and proteomics application for target identification; host cell proteins characterization, and mechanism ...

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in ...

As ATUM’s Co-Founder, Dr. Claes Gustafsson oversees most of the company’s external communications and is actively engaged in developing ATUM's technology platforms. Prior to co-founding ATUM in 2003, Claes managed key strategic teams at Maxygen Inc and worked as a scientist at Kosan...

Ana Isabel Gutiérrez joined H&T Presspart in 2023 as Global Business Development Manager driving the company’s innovative Parenteral Applications Program.Before joining H&T Presspart, Ana spent over 12 years at West Pharmaceutical Services, where she held a prominent sales leadership...

Anissa Harbi is an Immunologist MD from Annaba, Algeria, with a strong background in clinical research and patient care. Currently serving as an Immunologist at Les Hôpitaux d'Alger, Anissa is dedicated to advancing medical knowledge and improving patient outcomes.

Julia Harwardt is a Bench Scientist in the Antibody Discovery & Protein Engineering department at Merck KGaA. She joined the company after completing her PhD in the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. With a strong background in biochemistry and antibody...

Luluah Hashim Husain is a seasoned finance professional with a strong background in the biopharmaceutical industry. Currently serving as the Global Head of Finance for Biosimilars at Biogen, Luluah brings a wealth of experience and expertise to her role. With a proven track record of driving...

Winston is the VP Computational Sciences and Engineering at LabGenius, where he leads a team of experts in data science, machine learning, and software development to expand LabGenius’ ML-driven discovery platform capabilities. He has extensive experience leading the development and application of ...

Hooman is currently an Associate Professor at the Technical University of Denmark where his research group broadly aims to engineer mammalian cells for improved cellular behavior in fields including biologics manufacturing and cultivated meat. He previously led the Omics and Modeling Team in...

Charles Heise is Associate Director in the Bioprocessing Strategy & Development group at FUJIFILM Biotechnologies working on developing connected, integrated processes.  He has over 15 years of experience in the biologics industry leading the development of cGMP processes for clinical and...

As Head of Corporate Scientific Engagement at Genedata, Jana leads the advancement of data, analytics, data science, and AI within the biopharma R&D landscape. Since joining Genedata in 2018, Jana has held several positions shaping product development, marketing strategies, and scientific...

Oliver Hill – Senior Director Protein Engineering, YUMAB GmbH Oliver Hill is an experienced biotechnology professional specializing in protein engineering and drug discovery. Currently, he serves as Senior Director of Protein Engineering at YUMAB GmbH, focusing on advancing antibody-based...

Axel joined Bioassay in 2007 as Scientists after covering the role of Laboratory Head of Department of Cell and Molecular Biology at Biotest AG. Upon joining Bioassay Axel quickly rose through the ranks and became Managing Director in 2010. In his new role he was involved in the acquisition of...

Sebastian Hörner joined BiconY Therapeutics as a Senior Scientist in 2023. He studied technical biology at the University of Stuttgart from 2011 to 2017, where he started his work in the field of recombinant antibodies in the lab of Roland Kontermann. From 2017 to 2021, he worked as a PhD candidate ...

Originally from Canada, Dr. Melita Irving began working in the field of T-cell engineering for cancer immunotherapy in Switzerland in 2007. She has been a group leader at the Ludwig Institute for Cancer Research in the Department of Oncology at the University of Lausanne for the past 12...

Master in Political Science from the University of Copenhagen 45+ years of professional experience, including: Head of section in the Ministries of Social Affairs and of LabourLabour Counsellor at the Danish UN-mission in GenevaHealth Counsellor at the Danish EU-representation in BrusselsSpokesman...

Translational B cell and cancer immunologist with academic and biotechnology experience in the UK and USA. She heads a cancer antibody discovery team focusing on dissecting the crosstalk between human immunity and solid tumours and understanding the impact of antibody isotype on therapeutic...

Inventor of the P5 Platform to generate stable ADCs during Phd with Prof. Christian HackenbergerJoint Tubulis as Co-Founder in 2019Leads Tubulis Chemistry and Early Discovery efforts as VP

Dr. Hans Keirstead is an internationally recognized stem cell expert and successful entrepreneur. Known for developing treatments for quadriplegic spinal cord injury, cancer therapies for melanoma, brain, and ovarian cancers, and a multi-pathogen vaccine, he has also advanced therapeutic research...

Bertolt is an expert in cancer drug discovery with 20 years of pharmaceutical industry experience and a broad background in oncology research covering target validation, biologics and small molecule lead discovery, as well as research supporting pre-IND, early and late-stage clinical development...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research. For the last 19 years Dan has been working with analytical development in the biopharmaceutical...

Peter Kristensen is Professor at the Department of Chemistry and Bioscience, Aalborg University, Denmark. He holds a Ph.D. and M.Sc. in Biostructural Chemistry from the University of Aarhus. With a career spanning over two decades, his academic journey is marked by significant contributions to...

2024Yumab GmbH VP Services & Operations2016-2024Yumab GmbH Project manager2014-2016Technical University of BraunschweigPhD student, Department of Biotechnology.2008-2014University of Heidelberg Study of Molecular Biotechnology (Bsc/Msc).

Mayra Latorre-Martinez currently works at Swissmedic, in the Department of Clinical Trials where she is responsible for the evaluation and authorization of Clinical Trials. She is also Swissmedic representative at the Access Consortium Clinical Trials Working Group. Mayra worked at the Regulatory...

Britta Lipinski is a PhD candidate in the Antibody Discovery and Protein Engineering Department of Merck KGaA, supervised by Stefan Zielonka, where she works in close collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research focuses on the...

Dr. Margaux Fresnais obtained her PhD of chemistry at the University of Strasbourg (France) in 2016. Since then, she dedicated her activities to the development of mass spectrometric (MS) methods for targeting therapeutic antibodies and small-compound pharmaceuticals for personalized medicine. She...

Dr. Rémi Longuespée obtained a PhD in Life Sciences at the University of Lille (France) and a PhD of Biochemistry at the University of Sherbrooke (Canada) in 2012. He dedicated a major part of his career to the development of methods in mass spectrometry for applications in clinics, from anatomical ...

Christian Lotz studied Physical Chemistry at the University of Bochum Germany and did his doctorate in Physical Chemistry at the University of Essen in Germany. He started his Industry career at Lipoid GmbH, a GMP manufacturer of parenteral grade phospholipids, in the sales department with...

Robin Löving, Chief Scientific Officer (CSO) at Salipro Biotech. Robin has more than 15 years’ experience working with therapeutically interesting membrane proteins. He did his PhD with a focus on membrane proteins and antigen design at the Karolinska Institute in Stockholm, Sweden. After being...

Bernard Maillere is head of the Laboratory of Cellular Immunology and Biotechnology of the CEA, a French governmental research institute. He  is also head of the immunology section of the doctoral school "therapeutic innovation" of the University of Paris-Saclay. He holds a Master's...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

Aimee Mattei, MS. is the Director of Bioinformatics at EpiVax. She manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects. She leads the development of novel in silico methods and tools for...

Virginia Metrangolo is a Medical biotechnologist working as a postdoctoral researcher in the Engelholm research group at the Finsen Laboratory/Biotech Research and Innovation Centre in Copenhagen. Her research work involves the development of antibody-based therapies, mostly antibody-drug...

Since 2024, Lorenzo has worked as an independent advisor, collaborating with national governments and international organizations to promote partnerships for medicine development and strengthen regulatory systems. Previously, he led the work on access to innovative treatments and technologies at...

Julien's career has been devoted to the discovery & development of new technologies to help solve of the world's most complex design challenges, from the treatment of human diseases by creating new therapeutic libraries, to the manufacture of smart nano-electronics & 3D...

Dr. Lukas Naumann is a dedicated Scientist specializing in Analytical Chemistry with a focus on Process Analytical Technology (PAT) at Roche. With a strong background in biochemistry and pharmaceutical sciences, Lukas brings a wealth of expertise to the field of biologics. His research interests...

Björn Niebel is a Senior Principal Scientist, Group Head in the Discovery Department of the Nanobody Research Platform at Sanofi Ghent. Björn received his master’s degree in Chemistry from the University of Braunschweig, Germany in 2006 and holds a PhD in Biochemistry from the University of...

Aline de Almeida Oliveira holds a Bachelor's degree in Biological Sciences from the State University of Rio de Janeiro (2004), a Master's degree (2007), and a PhD (2011) in Oncology from the National Cancer Institute. She currently works at Bio-Manguinhos at Fiocruz, where she works at the...

Sandip is a downstream scientist at the Gene Therapy Process Sciences division of UCB Pharma in Belgium. He has worked for different organizations for 13 years, developing downstream processes for various biopharmaceuticals, such as fusion proteins, viral vectors, monoclonal antibodies, and...

Anikó Pálfi is Director Biochemistry and Cell Biology at Heidelberg Pharma Research GmbH, a pharma company located near Heidelberg (Germany), mainly conducting research and development of anti-cancer drugs. She obtained her bachelor’s degree in bioscience at the University of Heidelberg in 2012 and ...

Lewis is currently an advanced research fellow at the University of Aberdeen where he completed his PhD. In partnership with TauRx Therapeutics Ltd. and the Scottish Biologics Facility, his research is involved in the discovery and development of novel anti-tau therapeutics, immunodiagnostics and...

Isabelle Petit Topin is a passionate professional for Protein biochemistry and all that has to do with protein in general. Graduated at the University Paris Diderot, Isabelle obtained her PhD in 2009 (CIFRE HRA Pharma - Inserm - Paris) in Protein Biochemistry and Crystallography. After her...

Dr. Birgit Piater is an accomplished scientist with over ten years of experience in the pharmaceutical industry, currently serving as the Head of Laboratory for Antibody Drug Conjugates (ADC) Biology at Merck KGaA, Darmstadt, Germany. In her role, she leads a dynamic lab team focused on advancing...

Philipp Probst is Director of ADC Research at Araris Biotech AG, a Swiss biotech company located in Au ZH pioneering a novel linker technology for antibody-drug conjugates. He studied Pharmaceutical Sciences and received his PhD from ETH Zürich in 2018, where he worked in the group of Prof. Dario...

Chief Operating Officer of the Philogen Group and Board Member of Philochem AG (Philogen discovery center). Graduated in Medicinal Chemistry at La Sapienza University and performed Ph.D. studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of...

Dr Andy Racher is the Director of Commercial Operations at SynGenSys Ltd. With over four decades in the biotech sector, including a distinguished 20-year tenure at Lonza Biologics, Andy has a wealth of experience covering cell engineering, expression systems, cell line and process development, plus ...

Dr. Rafei is an immunologist by training focused on the development of therapies within the immuno-oncology space. Throughout the past decade, he accumulated profound knowledge and insight in the fields of T-cell development, stem cell biology, cancer immunotherapy and autoimmune diseases. While...

Alexander joined Anaveon in 2022 as a protein engineer, focused on developing the next generation of antibody-cytokine fusion proteins for cancer therapy. He previously worked at a biotech company, focusing on the generation of antibody therapeutics for immuno-oncology. He also has a strong...

Professor in directed evolution and antibody technology at KTH Royal Inst.Technology, Sweden. Director of GeneNova, a center focused on developing platforms for more cost effective, safe and efficacious AAV-based gene therapy through interdisciplinary industry and academia collaborations. He is an...

Thomas Rose, PhD, is Head of Expression Systems at ProBioGen. He received his MSc in Biotechnology from the University of Applied Science in Berlin, his PhD in Biochemistry from the Free University of Berlin and joined ProBioGen in 2001. His work focuses on cell line development and expression...

Christine Rothe serves as Chief Development Officer at iOmx Therapeutics where she is responsible for research and development programs. Christine has a long-standing track record in discovery and development of drug candidates. Before joining iOmx, Christine held positions of increasing...

Izabela Sabala brings a strong background in protein biochemistry, along with deep insight and practical strategies to her work. Her research is focused on engineering of a new class of antimicrobials—enzybiotics. These are enzymes with exceptional antimicrobial activity, currently being developed...

Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany.  Since then, he held positions of increasing responsibility in the R&D departments of...

Aaron is the Chief Strategy Officer at Adimab, with over 25 years of experience in biotechnology, focusing on discovering and developing novel first-in-class antibody therapeutics. Before joining Adimab, Aaron served as the Chief Scientific Officer of Twist Bioscience, where he led their Biopharma...

Christian is the co-founder and CSO of the biotech company Numaferm that was founded 2017 as a spin-off of the University of Düsseldorf, Germany. He is biochemist and biotechnologist by education and completed his PhD in the field of type 1 secretion systems at the same university between 2009 and...

Oliver Seifert is a senior scientist in the laboratory of Roland Kontermann at the University of Stuttgart and leads the bispecific antibody group. He is an expert in the field of antibody engineering with more than 20 years experience. His scientific research covers development and...

Cláudia is a trained Pharmacist and obtained her MSc from the University of Coimbra, in Portugal. She started her career at a CDMO with a focus on cell line and cell culture development. Cláudia joined the USP team at CDR-Life over two years ago and is now Lead Scientist in the Drug Substance...

Frank Staal was trained in biomedicine at the Faculty of Medicine of Utrecht University, the Netherlands. He obtained both his Bachelor and Master degrees cum laude from this university and then moved to Stanford University, CA USA, for his PhD degree in Genetics under supervision of the late...

After earning his degree in Medicine in 2009 from the Campus Bio-Medico University of Rome, he completed an international PhD in type 1 (autoimmune) diabetes at the same university and at Queen Mary, University of London (supervisor Prof. Ahuva Nissim). He subsequently obtained his specialty in...

Dr. Svilenov is an Associate Professor of Biopharmaceutical Technology at the Technical University of Munich (TUM). His research focuses on the development, formulation, and manufacturing of biotherapeutics. In 2024, he was awarded an ERC grant to advance novel antibody-based therapeutics.Prior to...

Hamed T. Ghomi is a scientist with over a decade of experience in computational molecular design, with a focus on peptide and protein engineering. He has led projects across industry and academia, including roles at companies such as Illumina, where he contributed to innovations in enzyme design...

Jian Tang is an Associate professor at HEC's Department of Decision Sciences. He is also an Adjunct professor at the Department of Computer Science and Operations Research at University of Montreal and a Core Academic member at Mila - Quebec AI Institute. He is a Canada CIFAR AI Chair and the...

Anike Te is an industrial strategist, honorary professor and advisor focused on strategic growth and innovation. Anike was appointed as Chief Strategy Officer of Lucideon in 2018, where she previously served on Lucideon’s Group Business Development Board and is currently a member of the Strategy...

Bert is currently Senior Vice President, Business Development of Bio-Thera Solutions, a China-based pharmaceutical company, joining the company in 2017. Prior to joining Bio-Thera Solutions, Bert was the CEO of the Sarcoma Foundation of America (SFA), a rare cancer patient advocacy...

Dr. Jakub Tomala earned his Master Science degree and Ph.D., both in Immunology, at Charles University in Prague, Czech Republic. After completing a postdoctoral fellowship at Johns Hopkins University, School of Medicine, in 2018, Dr. Tomala became senior researcher in the Laboratory of...

Dr. Marco Traub has gained considerable experience in several research, management, and educational projects over the past 25 years. He is the founder of the Trans European Stem Cell Therapy Consortium (TESCT) and acts since 2005 as Chair of the TESCT consortium and as EU-Commission Expert...

Laura Unmuth is a Bench Scientist and PhD candidate in the Antibody Discovery & Protein Engineering department of Merck KGaA, supervised by Stefan Zielonka and in collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research work focuses on the...

Stefanie Urlinger is Chief Scientific Officer at Cimeio Therapeutics, where she heads Research and Discovery. Stefanie has over 20 years of experience in large molecule engineering and early development and has led antibody discovery efforts as well as the development of antibody platform...

Thomas Valerius studied medicine at the University of Erlangen-Nürnberg, Germany. After his training in internal medicine, he specialized in Hematology/Oncology and Rheumatology. Since May 2003, he has been working at the University in Kiel, Germany, where he currently is assistant professor at the ...

Joshi Venugopal is the General Manager and Head of Europe for Novartis Gene Therapies &Rare Diseases. He is also a Board Member of Somagenetix, a Zurich based biotech company developing gene therapies. A seasoned pharmaceutical executive, Joshi brings a unique blend of experience across...

Dr. Wouter Verdurmen is an Assistant Professor at Radboud University Medical Center, specializing in biologics and immunotherapy. He studied Biomedical Sciences at Radboud University Nijmegen (the Netherlands) and obtained his PhD cum laude in 2012, focusing on the cellular delivery of...

2015-2020: Scientist at Genentech,Since 2020: Head of Biology / VP, Biology and Translational Research at TubulisScientific training background: molecular cell biology, protein degradation, cellular protein homeostasis

Bjørn Voldborg has more than 20 years of experience working with recombinant protein expression from both academic and industrial settings. From 2001-2008, Bjørn was team leader in the biotech company Pharmexa A/S, responsible for molecular cloning and expression of protein-based drug...

Meenu Wadhwa heads a team in the R&D Biotherapeutics and Advanced Therapies group at the MHRA, UK. Areas of interest are development and application of assays – potency, bioanalytical (e.g., cytokines and related products, anti-drug antibody assays), biosimilars, unwanted immunogenicity and...

Born in Bochum, Germany, in 1984, with a passion for science and a drive for discoveryStudied biochemistry at the Ruhr University Bochum, graduating with a Master of Science in Biochemistry in 2009Awarded a Ph.D. (summa cum laude) in Chemistry and Biochemistry from Heinrich-Heine University...

I am a Group Leader at Cancer Research Horizons and the CRUK lead for the Joint AZ-CRH Functional Genomics Centre. With over 10 years' experience, I specialise in functional genomics and preclinical oncology R&D. Before joining Cancer Research Horizons in 2019, I led target discovery and...

Jörg Wischhusen studied biochemistry in Tübingen, Germany. During his thesis on mechanisms of immune escape in glioma (mentored by Michael Weller and Hans-Georg Rammensee) he performed early work in the field of experimental immune checkpoint blockade. In 2005 he was recruited as a junior research...

Frederick joined MSD in November 2016 to build a European Vaccines Clinical Development Unit in Europe. His team now has four members. This team designs, sets-up, conducts, monitors, analyzes, closes out and publishes clinical trials and PDTs within a broader clinical trial teams for vaccine...

Dr. Yi-Ru Yu is currently a Senior Scientist at Pilatus Biosciences SA. He obtained his B.S. in Life Science and M.S. in Genomic Science from National Yang-Ming University in 2008. Dr. Yu then pursued a Ph.D. in Prof. Chun-Ming Chen's lab, where his research focused on the congenital diseases...

My passion are science and people. Hence,  it appealed to me to study medicine and following undergraduate studies in Berlin, I went into surgery in the UK and Germany,  and eventually I found my passion in surgical oncology, caring for patients with breast cancer, sarcoma, melanoma and many other...